Search results for "LSA"

showing 10 items of 832 documents

Behavioral Effects of GABAA Receptor Stimulation and GABA-Transporter Inhibition

2000

Abstract The present analysis addressed behavioral changes after treatment with 4.5 mg/kg or 18.5 mg/kg of the GABA-uptake inhibitor tiagabine combined with either the benzodiazepine diazepam (1.5 mg/kg) or the imidazopyridine zolpidem (0.05 mg/kg), the latter two acting differentially on GABA A receptor subtypes. The study included 97 male PVG/OIaHsd rats. A standard open field, an enriched open field, and an elevated plus-maze was used to study rat behavior. Treatment with the low dose of tiagabine alone induced no specific behavioral effects, whereas the high dose had an anxiolytic-like potential. Furthermore, diazepam but not zolpidem displayed anxiolytic-like effects. Combination of ea…

MaleAgonistGABA Plasma Membrane Transport Proteinsmedicine.medical_specialtyZolpidemTiagabinePyridinesmedicine.drug_classmedicine.medical_treatmentClinical BiochemistryNipecotic AcidsOrganic Anion TransportersMotor ActivityPharmacologyToxicologyBiochemistryOpen fieldBehavioral NeuroscienceInternal medicinemedicineAnimalsHypnotics and SedativesDrug InteractionsNeurotransmitter Uptake InhibitorsTiagabineBiological PsychiatryPharmacologyBenzodiazepineBehavior AnimalChemistryGABAA receptorMembrane ProteinsMembrane Transport ProteinsReceptors GABA-ARatsZolpidemEndocrinologyAnticonvulsantDrug Therapy CombinationCarrier ProteinsDiazepammedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Two-dimensional transthoracic echocardiographic normal reference ranges for proximal aorta dimensions: Results from the EACVI NORRE study

2017

International audience; AIMS: To report normal reference ranges for echocardiographic dimensions of the proximal aorta obtained in a large group of healthy volunteers recruited using state-of-the-art cardiac ultrasound equipment, considering different measurement conventions, and taking into account gender, age, and body size of individuals. METHODS AND RESULTS: A total of 704 (mean age: 46.0 ± 13.5 years) healthy volunteers (310 men and 394 women) were prospectively recruited from the collaborating institutions of the Normal Reference Ranges for Echocardiography (NORRE) study. A comprehensive echocardiographic examination was obtained in all subjects following pre-defined protocols. Aortic…

MaleAorta ThoracicSex Factor030204 cardiovascular system & hematologyReproducibility of resultCohort Studies0302 clinical medicineDiastoleMedicineThoracic aortaAge FactorReference ValueProspective Studies030212 general & internal medicineMultivariate AnalysiBody surface areaCardiac cycleAge FactorsGeneral MedicineNORRE studyMiddle AgedHealthy VolunteerHealthy VolunteersEuropeEchocardiographyNORRE study; echocardiography; reference values; reproducibility of results; sinus of valsalva; thoracic aortaCardiologyLinear Model[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtySystoleDiastoleNormal valuesThoracic aortaReference values03 medical and health sciencesYoung AdultSex FactorsInternal medicinemedicine.arteryAscending aortaHumansRadiology Nuclear Medicine and imagingMeasurement methodAortaAnalysis of Variancebusiness.industrySinus of valsalvaReproducibility of ResultsMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREProspective StudieMultivariate AnalysisLinear ModelsCohort Studiebusiness
researchProduct

Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs).

2004

Carbenoxolone (CBX), the succinyl ester of glycyrrhetinic acid, is an inhibitor of gap junctional intercellular communication. Systemic administration of CBX was able to decrease the seizure severity score and to increase the latency time of seizure onset in genetically epilepsy prone rats (GEPRs). In particular, intravenous or intraperitoneal administration of carbenoxolone (5-30 mg/kg) produced a dose-dependent and significant reduction in the clonic and tonic phases of the audiogenic seizures in GEPRs. The anticonvulsant doses were not associated with an impairment of motor coordination. The bilateral microinjection of CBX (0.001-0.50 microg/0.5 microl) into the inferior colliculi, the s…

MaleAudiogenic seizuremedicine.medical_treatmentGap junctionGEPR-9sCarbenoxoloneSubstantia nigraPharmacologyConnexinConnexinsRats Sprague-DawleyCellular and Molecular NeuroscienceEpilepsyMedicineAnimalsMicroinjectionPharmacologyEpilepsybusiness.industrymedicine.diseaseMotor coordinationRatsAnticonvulsantAnesthesiaSystemic administrationCarbenoxoloneAnticonvulsantsFemalebusinessPars reticulataGEPR-3medicine.drugNeuropharmacology
researchProduct

The Anticonvulsant FCE 26743 is a Selective and Short-acting MAO-B Inhibitor Devoid of Inducing Properties towards Cytochrome P450-dependent Testoste…

1994

Abstract The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-(3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10−7  m for MAO-B and higher than 10−5  m for MAO-A. When determined ex-vivo in brain, the ED50 value for the inhibition of MAO-B was 1·1 mg kg−1 (p.o.) 1 h post-dosing, whereas MAO-A remained virtually unaffected after administration of 60 mg kg−1. Similar effects were seen in liver. Following oral administration of 5 mg kg−1 FCE 26743 to rats, brain MAO-B inhibitio…

MaleBenzylaminesMonoamine Oxidase InhibitorsMonoamine oxidaseMetabolite3003 Pharmaceutical Science10050 Institute of Pharmacology and ToxicologyPharmaceutical Science610 Medicine & healthMice Inbred StrainsIn Vitro TechniquesPharmacologyHydroxylationRats Sprague-DawleyHydroxylationMicechemistry.chemical_compoundCytochrome P-450 Enzyme SystemOral administrationmedicineAnimalsTestosteroneED50PharmacologyAlanineDose-Response Relationship DrugbiologyChemistryBrainCytochrome P450Rats3004 PharmacologyLiverMechanism of actionbiology.protein570 Life sciences; biologyAnticonvulsantsMonoamine oxidase Bmedicine.symptomJournal of Pharmacy and Pharmacology
researchProduct

Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm

2007

Botulinum toxin (BTX) is the medical therapy of choice in hemifacial spasm (HFS). However, in some patients, its therapeutic effect is insufficient. ### Patient 1. A 64-year-old man with a 10-year history of left-sided HFS was treated with BTX over a period of 6 years with good results. However, in the last 2 years the spasms were never sufficiently relieved by BTX. The patient felt significantly impaired, but declined to undergo neurosurgical intervention. The EDB test showed a decrease in the CMAP amplitude of 60%. Without changing the BTX regime, pregabalin (initially 75 mg/day increased every 5 days by 75 mg to 150 mg twice daily) was added for a 1-month trial period in the absence of a…

MaleBotulinum ToxinsPregabalinPregabalinPhysiology (medical)medicineHumansHemifacial SpasmAdverse effectgamma-Aminobutyric AcidAnti-Dyskinesia Agentsbusiness.industryTherapeutic effectMiddle Agedmedicine.diseaseBotulinum toxinSensory SystemsDiscontinuationDrug CombinationsTreatment OutcomeAdd on treatmentNeurologyAnesthesiaAnticonvulsantsFemaleNeurology (clinical)businessMedical therapymedicine.drugHemifacial spasmNeurology
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct

Interaction of uridine with GABA binding sites in cerebellar membranes of the rat

1983

The effect of uridine, a postulated anticonvulsant agent, on GABA receptors has been investigated. Uridine inhibits [3H]GABA binding to rat cerebellar buffer-washed membranes. Pretreatment of the membranes with Triton X-100 increases the effect of uridine on GABA-binding. The Scatchard analysis reveals that both high and low affinities of GABA for its receptors are affected by 1 mM uridine, while the apparent number of binding sites remains unchanged. The ability of uridine to interact competitively with GABA binding sites, also examined by the Lineweaver-Burk analysis, suggests a possible mechanism of action of this anticonvulsant agent, so including it among those compounds characterized …

MaleCerebellumReceptors Cell SurfaceBiologyBinding CompetitiveBiochemistrygamma-Aminobutyric acidCellular and Molecular Neurosciencechemistry.chemical_compoundGABA receptorCerebellummedicineAnimalsBinding siteReceptorUridinegamma-Aminobutyric AcidGABAA receptorCell MembraneRats Inbred StrainsGeneral MedicineReceptors GABA-AUridineRatsmedicine.anatomical_structurenervous systemBiochemistryMechanism of actionchemistryAnticonvulsantsmedicine.symptommedicine.drugNeurochemical Research
researchProduct

Transcriptomic profile of epileptic children treated with ketogenic therapies.

2022

Background: Ketogenic dietary therapies (KDT) are used as a treatment in childhood epilepsy. However, their mechanism has not yet been established. The main objective of this study was to determine the changes in the transcriptomic profile induced by KDT in children with epilepsy in order to shed light on its possible mechanisms. Methods: Eight children with refractory epilepsy were enrolled in the study. Peripheral blood mononuclear cells were obtained before and after the children were treated with KDT for a minimum of 6 months. RNA was extracted and mRNA and miRNA profiling were performed and analyzed. Results: Our intervention with KDT significantly reduced the seizure number in seven o…

MaleDrug Resistant EpilepsyGeneral NeurosciencesynapsismirnomeInfantketogenic dietary therapiesNeurosciences. Biological psychiatry. NeuropsychiatryGeneral MedicineMicroRNAsketogenic dietChild PreschoolOutcome Assessment Health CareepilepsyHumansFemaleanticonvulsantChildDiet KetogenicTranscriptomeRC321-571Journal of integrative neuroscience
researchProduct

N-Valproyl-L-Phenylalanine as new potential antiepileptic drug: Synthesis, characterization and in vitro studies on stability, toxicity and anticonvu…

2013

Valproic acid (VPA) is considered first-line drug in treatment of generalized idiopathic seizures such as absence, generalized tonic-clonic and myoclonic seizures. Among major antiepileptic drugs, VPA is also considered effective in childhood epilepsies and infantile spasms. Due to its broad activity, VPA acts as a mood stabilizer in bipolar disorder and it is useful in migraine prophylaxis. Despite its long-standing usage, severe reactions to VPA, such as liver toxicity and teratogenicity, are reported. To circumvent side effects due to structural characteristics of VPA, we synthesized in good yield a new VPA-aminoacid conjugate, the N-valproyl-L-Phenylalanine, and characterized by FT-IR, …

MaleDrugCell Membrane PermeabilityAminoacidic derivative Astrocytes toxicity CNS-Targeting Enzymatic Stability Hippocampal epilepsy Valproic acid.Cell Survivalmedicine.drug_classPhenylalaninemedicine.medical_treatmentmedia_common.quotation_subjectPrimary Cell CulturePhenylalaninePharmacologySettore BIO/09 - FisiologiaHippocampusTissue Culture TechniquesDrug StabilityDrug DiscoverymedicineAnimalsRats WistarEvoked Potentialsmedia_commonValproic AcidChemistryHydrolysisValproic AcidBiological TransportMood stabilizerMicrotomyHydrogen-Ion ConcentrationIn vitroRatsAnticonvulsantSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAstrocytesToxicityAnticonvulsantslipids (amino acids peptides and proteins)Conjugatemedicine.drug
researchProduct

Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents

2020

PURPOSE Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C/D) expected in a "normal" population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adul…

MaleDrugTopiramatePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentmedia_common.quotation_subjectPopulation030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsparasitic diseasesHumansMedicinePharmacology (medical)ChildeducationAntipsychoticOxcarbazepinemedia_commonPharmacologyeducation.field_of_studyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryAge FactorsArea under the curveAntidepressive AgentsTherapeutic drug monitoringArea Under CurveAnticonvulsantsCentral Nervous System StimulantsFemaleDrug MonitoringbusinessAntipsychotic AgentsHalf-Lifemedicine.drugTherapeutic Drug Monitoring
researchProduct